Article

Some Rheumatoid Arthritis Patients Have Elevated Monosodium Urate Deposits

Author(s):

A considerable number of patients who suffer from rheumatoid arthritis display periarticular monosodium urate deposits.

A study in Seminars in Arthritis & Rheumatism suggests that a considerable number of patients who suffer from rheumatoid arthritis (RA) display periarticular monosodium urate (MSU) deposits.

The findings are potentially important because while the differences between the presentation, etiology, and pathophysiology between gout and RA are generally well-understood, there is currently no known single cause for RA. Recent improvements in imaging techniques that detect urate disposition may allow clinicians to target hyperuricemia before crippling symptoms even begin, and may get researchers to a deeper understanding of what specific factors cause RA. Early treatment of gout, RA, and other inflammatory diseases is widely considered to be essential for the growing number of patients who suffer from them.

In the current prospective study, 100 consecutive patients with RA and a serum urate level above 6 mg/dl underwent dual energy computed tomography (DECT) of both feet and hands to search for MSU crystals. The presence and proliferation of MSU crystal deposits on the test was assessed by automated volume measurement. Demographic information and disease-specific characteristics were recorded and included into logistic regression models to test for the factors associated with MSU crystal deposits in RA.

Those RA patients with hyperuricemia were mostly male (55%), over 60 years of age (63±11 years), had established disease (8.7±10.5 years), and had a mean disease activity score 28 (DAS 28) of 3.2. Twenty out of 100 patients displayed MSU crystal deposits in DECT.

The study may also contribute to the growing understanding about how seropositive and seronegative cases of RA progress and how they can be treated. In the current study, the majority (70%) of the RA patients positive for MSU crystal deposits were seronegative RA patients. Every third seronegative RA patient had MSU crystal deposits. According to logistic regression model analysis, seronegative status correlated positively with presence of urate deposits (p=0.019).

Gout tends to be more treatable than RA, but further research into the role and behavior of MSU crystal deposits could lead to enhancements in RA care. The researchers would like to see larger clinical studies that further establish the connection between MSU crystals and some RA cases.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2024 MJH Life Sciences

All rights reserved.